Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
August 17, 2020 at 01:10 pm IST
Share
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 1,174.552 million compared to CNY 1,168.694 million a year ago. Operating income was CNY 209.143 million compared to CNY 216.838 million a year ago. Net income was CNY 177.374 million compared to CNY 183.518 million a year ago. Basic earnings per share from continuing operations was CNY 0.312 compared to CNY 0.314 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.